Comparison 13. Anticoagulants versus control: serious adverse events.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
13.1 Serious adverse events: DOAC vs placebo	2	934	Risk Ratio (IV, Random, 95% CI)	0.96 [0.82, 1.13]
13.2 Serious adverse events: LMWH vs no thromboprophylaxis	5	1531	Risk Ratio (IV, Random, 95% CI)	0.86 [0.70, 1.07]
13.2.1 Dalteparin	3	343	Risk Ratio (IV, Random, 95% CI)	1.22 [0.45, 3.34]
13.2.2 Nadroparin	1	1150	Risk Ratio (IV, Random, 95% CI)	0.89 [0.68, 1.17]
13.2.3 Bemiparin	1	38	Risk Ratio (IV, Random, 95% CI)	0.75 [0.43, 1.30]
13.3 Serious adverse events: semuloparin vs placebo	1	3172	Risk Ratio (IV, Fixed, 95% CI)	1.03 [0.92, 1.16]